Chemistry:XC-130

From HandWiki

XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease.[1][2][3][4] It is taken orally.[1][3][4]

The drug is a dopamine D2 receptor partial agonist, a dopamine D3 receptor antagonist, an α1A-adrenergic receptor antagonist, and a serotonin 5-HT1B, 5-HT2A, and 5-HT2B receptor antagonist.[3] Its potency as a dopamine D2 receptor agonist is similar to that of lisuride.[3] XC-130 produces antiparkinsonian-like effects in animals.[4] Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D3 agonism), vasoconstriction (related to α1A-adrenergic and 5-HT1B agonism), hallucinogenic effects (related to 5-HT2A agonism), and cardiac valvulopathy (related to 5-HT2B agonism).[3] It has a notably longer elimination half-life than the relatively short-acting lisuride.[3] The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile.[3][4]

XC-130 is under development by Xoc Pharmaceuticals.[1][2] As of November 2022, it is in phase 1/2 clinical trials.[1][2] The chemical structure of XC-130 does not yet appear to have been disclosed.[1]

See also

  • List of investigational Parkinson's disease drugs
  • XC-101-D13H (XC-101)

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "XC 130". 28 November 2022. https://adisinsight.springer.com/drugs/800051261. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on XC130-A10H with Synapse". 8 May 2025. https://synapse.patsnap.com/drug/5ce300e8f1f64e8db21a78008059d2ea. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "In Vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety (4465)". Neurology 96 (15_supplement). 13 April 2021. doi:10.1212/WNL.96.15_supplement.4465. ISSN 0028-3878. https://www.neurology.org/doi/10.1212/WNL.96.15_supplement.4465. Retrieved 25 January 2026. 
  4. ↑ 4.0 4.1 4.2 4.3 "Assessment of a Novel Long Lasting Dopamine Agonist in the Unilateral 6-OHDA Lesion Model of Parkinson's Disease (4480)". Neurology 96 (15_supplement). 13 April 2021. doi:10.1212/WNL.96.15_supplement.4480. ISSN 0028-3878. https://www.neurology.org/doi/10.1212/WNL.96.15_supplement.4480. Retrieved 25 January 2026. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:XC-130&oldid=4309013"